Published in Neuropathology on May 12, 2015
Alzheimer's disease: experimental models and reality. Acta Neuropathol (2016) 0.88
Clinical Features of Alzheimer Disease With and Without Lewy Bodies. JAMA Neurol (2015) 0.85
White matter hyperintensities are a core feature of Alzheimer's disease: Evidence from the dominantly inherited Alzheimer network. Ann Neurol (2016) 0.82
Amyloid negativity in patients with clinically diagnosed Alzheimer disease and MCI. Neurology (2016) 0.79
Clinically early-stage CSPα mutation carrier exhibits remarkable terminal stage neuronal pathology with minimal evidence of synaptic loss. Acta Neuropathol Commun (2015) 0.78
Coupled Harmonic Bases for Longitudinal Characterization of Brain Networks. Proc IEEE Comput Soc Conf Comput Vis Pattern Recognit (2016) 0.75
Differentiating cognitive impairment due to corticobasal degeneration and Alzheimer disease. Neurology (2017) 0.75
Phenotypic Similarities Between Late-Onset Autosomal Dominant and Sporadic Alzheimer Disease: A Single-Family Case-Control Study. JAMA Neurol (2016) 0.75
Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology (1993) 16.92
Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med (2012) 14.14
Diagnosis of Alzheimer's disease. Arch Neurol (1985) 12.77
Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology (1996) 12.33
Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease. Neurobiol Aging (1997) 10.81
Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. Ann Neurol (1999) 10.45
Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration. Acta Neuropathol (2007) 8.10
Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer's disease. J Neurosci (1996) 7.19
APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol (2010) 6.17
National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. Acta Neuropathol (2011) 6.00
Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update. Acta Neuropathol (2009) 4.73
Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease. Neurobiol Aging (2009) 4.36
The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception. Alzheimers Dement (2011) 4.25
The Alzheimer's disease neuroimaging initiative: progress report and future plans. Alzheimers Dement (2010) 3.85
Cerebral amyloid deposition and diffuse plaques in "normal" aging: Evidence for presymptomatic and very mild Alzheimer's disease. Neurology (1996) 3.29
The distribution of tangles, plaques and related immunohistochemical markers in healthy aging and Alzheimer's disease. Neurobiol Aging (1992) 2.97
Human postmortem tissue: what quality markers matter? Brain Res (2006) 2.92
The CERAD neuropathology protocol and consensus recommendations for the postmortem diagnosis of Alzheimer's disease: a commentary. Neurobiol Aging (1997) 2.72
Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the Consortium on DLB International Workshop. J Alzheimers Dis (2006) 2.41
Twenty-first century brain banking. Processing brains for research: the Columbia University methods. Acta Neuropathol (2007) 1.94
Developing an international network for Alzheimer research: The Dominantly Inherited Alzheimer Network. Clin Investig (Lond) (2012) 1.90
Postmortem interval effect on RNA and gene expression in human brain tissue. Cell Tissue Bank (2010) 1.46
Clinical and multimodal biomarker correlates of ADNI neuropathological findings. Acta Neuropathol Commun (2013) 1.15
Inter-laboratory comparison of neuropathological assessments of beta-amyloid protein: a study of the BrainNet Europe consortium. Acta Neuropathol (2008) 1.13
Predominant deposition of amyloid-beta 42(43) in plaques in cases of Alzheimer's disease and hereditary cerebral hemorrhage associated with mutations in the amyloid precursor protein gene. Am J Pathol (1996) 1.12
Synaptic loss and pathological change in older adults--aging versus disease? Neurobiol Aging (2001) 0.87
Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med (2012) 14.14
CD33 Alzheimer's disease locus: altered monocyte function and amyloid biology. Nat Neurosci (2013) 2.51
Predicting clinical scores from magnetic resonance scans in Alzheimer's disease. Neuroimage (2010) 2.33
Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer's disease. Nat Med (2019) 2.03
Factors associated with the onset and persistence of post-lumbar puncture headache. JAMA Neurol (2015) 1.78
Symptom onset in autosomal dominant Alzheimer disease: a systematic review and meta-analysis. Neurology (2014) 1.47
Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer's disease. Sci Transl Med (2014) 1.45
Early changes in CSF sTREM2 in dominantly inherited Alzheimer's disease occur after amyloid deposition and neuronal injury. Sci Transl Med (2016) 1.44
Cerebral amyloidosis associated with cognitive decline in autosomal dominant Alzheimer disease. Neurology (2015) 1.40
Quantitative Amyloid Imaging in Autosomal Dominant Alzheimer's Disease: Results from the DIAN Study Group. PLoS One (2016) 1.38
Partial volume correction in quantitative amyloid imaging. Neuroimage (2014) 1.24
Accelerating cortical thinning: unique to dementia or universal in aging? Cereb Cortex (2012) 1.20
Critical ages in the life course of the adult brain: nonlinear subcortical aging. Neurobiol Aging (2013) 1.17
Comparison of imaging biomarkers in the Alzheimer Disease Neuroimaging Initiative and the Mayo Clinic Study of Aging. Arch Neurol (2012) 1.11
Identification of TMEM230 mutations in familial Parkinson's disease. Nat Genet (2016) 1.02
Greater regional brain atrophy rate in healthy elderly subjects with a history of cigarette smoking. Alzheimers Dement (2012) 0.98
Regional cortical thinning predicts worsening apathy and hallucinations across the Alzheimer disease spectrum. Am J Geriatr Psychiatry (2013) 0.87
Early behavioural changes in familial Alzheimer's disease in the Dominantly Inherited Alzheimer Network. Brain (2015) 0.83
White matter hyperintensities are a core feature of Alzheimer's disease: Evidence from the dominantly inherited Alzheimer network. Ann Neurol (2016) 0.82
Genetic heterogeneity in Alzheimer disease and implications for treatment strategies. Curr Neurol Neurosci Rep (2014) 0.82
Residual vectors for Alzheimer disease diagnosis and prognostication. Brain Behav (2011) 0.79
BDNF Val66Met moderates memory impairment, hippocampal function and tau in preclinical autosomal dominant Alzheimer's disease. Brain (2016) 0.78
Gray matter atrophy in patients with mild cognitive impairment/Alzheimer's disease over the course of developing delusions. Int J Geriatr Psychiatry (2015) 0.78
Generalizability of the disease state index prediction model for identifying patients progressing from mild cognitive impairment to Alzheimer's disease. J Alzheimers Dis (2015) 0.78
An Integrated Bioinformatics Approach for Identifying Genetic Markers that Predict Cerebrospinal Fluid Biomarker p-tau181/Aβ1-42 Ratio in ApoE4-Negative Mild Cognitive Impairment Patients. J Alzheimers Dis (2015) 0.76
Decreased platelet APP isoform ratios in autosomal dominant Alzheimer's disease: baseline data from a DIAN cohort subset. Curr Alzheimer Res (2015) 0.75
Correction: Quantitative Amyloid Imaging in Autosomal Dominant Alzheimer's Disease: Results from the DIAN Study Group. PLoS One (2016) 0.75
Rapidly progressive primary progressive aphasia and parkinsonism with novel GRN mutation. Mov Disord (2016) 0.75
Plasma Tau Association with Brain Atrophy in Mild Cognitive Impairment and Alzheimer's Disease. J Alzheimers Dis (2017) 0.75
Amyloid imaging of dutch-type hereditary cerebral amyloid angiopathy carriers. Ann Neurol (2019) 0.75
Longitudinal Partial Volume Correction in 2-[18F]-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography Studies of Alzheimer Disease. J Comput Assist Tomogr (2015) 0.75